✦ LIBER ✦

49. Five-year safety and efficacy of velaglucerase alfa in Gaucher disease type 1: Experience in clinic and home settings

✍ Scribed by Deborah Elstein; Ari Zimran; Gabriel M. Cohn; Kiran Bhirangi

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and Efficacy of Velaglucerase Alf

✍ Ari Zimran; Madhulika Kabra; Pilar Giraldo; Marie-Françoise Ben Dridi; Deborah E 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Two-Year Efficacy And Safety Of Velagluc

✍ Eric Crombez; Priya Kishnani; Hadhami Ben Turkia; Derlis Gonzalez; Ari Zimran; M 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Safety and efficacy of long-term enzyme

✍ Elstein, Deborah; Giraldo, Pilar; Mehta, Atul; Pastores, Gregory; Rhead, William 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 367 KB

A 7-year open-label study of clinical pa

✍ Elstein, Deborah; Cohn, Gabriel; Zahrieh, David; Crombez, Eric; Zimran, Ari 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Safety and efficacy of long-term velaglu

✍ Giraldo, Pilar; Zimran, Ari; Mehta, Atul; Hughes, Derralynn; Hangartner, Thomas 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 265 KB

TCT-197: Safety and Efficacy of Autologo

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 177 KB